Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions.

NCT02091908 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.

NCT NCT02091908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02091908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions.
Lead sponsor
Seqirus
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2014
Completion date
April 30, 2015
Enrollment
540 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human